Treatment News : Benefits of a Lowered HIV Pill Burden and Dosing Schedule

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 8, 2014

Benefits of a Lowered HIV Pill Burden and Dosing Schedule

A meta-analysis of the relative effects of both pill burden (the number of pills taken per day) and dosing frequency of antiretroviral (ARV) regimens has found that cocktails with fewer pills are linked to better drug adherence and virologic suppression, and that adherence is better among those on once- versus twice-daily regimens, but only modestly.

Publishing their findings in Clinical Infectious Diseases, researchers compiled 19 randomized controlled trials, including 6,312 participants, that compared once-daily with twice-daily ARV dosing and had information about adherence and virologic suppression.

The researchers found that, on average, adherence was modestly improved for those taking once-daily ARV regimens when compared with those taking twice-daily regimens. There was no difference in virologic suppression rates between the two groups, however. Adherence and virologic suppression rates both tapered among those taking once- or twice-daily regimens as time passed. However, these decreases were greater among those taking twice-daily doses.

Having to take a larger number of pills each day, regardless of whether the dosing schedule was once- or twice-daily, was linked with lower adherence and worse virologic suppression rates. But for those taking once-daily regimens, this difference was not statistically significant, meaning it could have happened by chance.

To read the study abstract, click here.

Search: Pill burden, dosing schedule, HIV, Clinical Infectious Diseases.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    soy_Ric
    Rochester
    New York


    Deelight4u
    BROOKLYN
    New York


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.